SCHEMBL2819947

SCHEMBL2819947

COc1ccccc1N1CCN(C(=O)[C@@H]2C[C@H](N(C)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)CN2Cc2cccc(Cl)c2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.49
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
GAA P10253 2/20 0.43
RBP4 P02753 1/20 0.40
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
DRD3 P35462 1/20 0.40
LMNA P02545 3/20 0.40
MAPT P10636 3/20 0.40
USP2 O75604 1/20 0.40
MC4R P32245 1/20 0.40
ALDH1A1 P00352 1/20 0.40
POLB P06746 3/20 0.39
KDM4E B2RXH2 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NOD2 Q9HC29 1/20 0.39
HTR7 P34969 1/20 0.39
TACR3 P29371 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3637175 0.94 NPC1 (0.51) NPC1KMT2AMEN1GAALMNA
SCHEMBL2822151 0.94 NPC1 (0.51) NPC1KMT2AMEN1GAALMNA
SCHEMBL2821138 0.91 CACNA1G (0.45) NPC1KMT2AMEN1GAALMNA
SCHEMBL2820107 0.89 MC4R (0.39) NPC1DRD2DRD4DRD3LMNA
SCHEMBL3640878 0.87 KMT2A (0.45) NPC1KMT2AMEN1GAADRD2
SCHEMBL2820989 0.87 KMT2A (0.45) NPC1KMT2AMEN1GAADRD2
SCHEMBL2817840 0.87 POLB (0.44) KMT2AMEN1LMNAMAPTALDH1A1
SCHEMBL3979720 0.85 NPBWR1 (0.42) KMT2AMEN1LMNAMAPTALDH1A1
SCHEMBL3641111 0.85 TACR3 (0.44) KMT2AGAALMNAALDH1A1POLB
SCHEMBL2820035 0.85 TACR3 (0.44) KMT2AGAALMNAALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155672-B1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-10-27 EP disclosed
US-7528136-B2 for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD); 2-{4-[(2S,4S)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
US-20080306086-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306086-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS SLC6A3, OPRL1, OPRK1 NPC1 1504/4885KMT2A 1350/4885MEN1 4786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.